SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is caught in a broader memory-stock selloff, with traders focused on concerns that Chinas CXMT could add competition and pressure sector pricing, alongside wider worries about AI valuations and macro conditions. The community is split between expecting further declines and viewing the China threat as overstated, arguing that SanDisks NAND business differs from CXMTs DRAM focus and that AI-related storage demand remains supportive.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSMCs Q3 results beat expectations and set records, reinforcing the view that AI-chip demand remains strong. Traders are divided on the market reaction: some see the report as validation of the AI semiconductor cycle, while others point to a sell-the-news move and broader risk-off pressure weighing on shares despite the strong results.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDA expanded Anktivas approval to include BCG-unresponsive papillary-only bladder cancer, broadening the eligible patient population and drawing intense attention to IBRX. Many traders see the decision as a major commercial and regulatory positive, while others are disappointed by the muted share-price reaction and question whether the news was already priced in; claims of short-driven suppression remain speculation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is under pressure amid a sharp South Korean semiconductor selloff, with traders citing fears of rising Chinese memory-chip competition, doubts about AI spending and broader macro concerns. Bulls argue the CXMT threat is overstated and view the pullback as a buying opportunity, while bears warn that competition and memory-cycle risks could prolong the decline.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Hotter-than-expected inflation has revived fears of further Fed rate hikes, alongside a selloff in AI and semiconductor stocks that is weighing on the broader index. Traders are split between viewing the decline as a buying opportunity and warning of a deeper correction, with upcoming inflation data in focus.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a broad technology and semiconductor selloff, with traders citing hotter-than-expected inflation and renewed fears of Federal Reserve rate hikes; weakness in South Korean markets and concerns about AI spending have added to the unease. The community is split between expecting further losses and viewing the pullback as a buying opportunity, with upcoming inflation data seen as a potential catalyst for direction.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is under pressure after pushing Neutrons first flight to 2027 because of carbon-composite tank manufacturing issues. Traders are split between viewing the delay as prudent quality control and seeing it as another execution setback that postpones growth; some consider the selloff an overreaction, while broader weakness in space stocks is also mentioned.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is under pressure as South Korean stocksespecially Samsung and SK Hynixsell off amid concerns about Chinese memory-chip competition, AI-sector weakness, and foreign investor outflows; its 3x leverage magnifies the moves. Traders are divided between buying the steep decline and warning that further losses and forced liquidations could follow.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is centered on Gartners warning that many neocloud providers may not remain independent, alongside concerns that the companys debt-heavy expansion could become harder to finance as its bond yields rise and inflation fuels rate worries. Traders are divided between fears of financial distress and an AI infrastructure downturn, and dip buyers who point to demand, backlog, and potential Nvidia support.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles sharp decline is being discussed amid a broader AI-stock selloff and hotter inflation that renewed concerns about interest rates and financing costs. Traders are split between viewing the debt-heavy AI data-center buildout and OpenAI exposure as major risks, and treating the drop as an overreaction and buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

Key PointsHe feels it's a clear buy at the current price...

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Equity

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.


Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Add LXRX Stock to Your Portfolio Now

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Key PointsLexicon Pharmaceuticals focuses on precision medicines for chronic conditions, bolstered by significant revenue growth from its core drug programs...

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average   - Here's What Happened

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average - Here's What Happened...

Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday

Lexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-lexicon-pharmaceuticals-inc-stock...

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High  - Here's Why

Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week High - What's Next...

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Lexicon Pharmaceuticals Inc

Bearish Sentiment

Hotter than expected

As expected

Cooler than expected

The September Producer Price Index report lands Thursday, October 15 at 8:30 AM ET, one day after CPI, with August’s reading at 5.4% year over year, as investors look for clues on inflation before the Fed’s October 27-28 meeting. How will the September PPI print compare to consensus expectations? Vote and explain your reasoning in the comments.

How will the September PPI print compare to consensus expectations?

Current Price	$1.60
Prev Close	$1.61
Open	$1.61
Dividend Yield	0.00%
50-Day Moving Average	$2.10
Beta	1.66
Avg. Volume	3.24M
PE Ratio	-10.45

52-Week High	$2.68
52-Week Low	$1.10
Market Capitalization	$716.38M
EPS (Annual)	-$0.1387
Price to Book	4.08
Revenue Per Employee	$614,851.85

Feed

News

Sentiment

Earnings

Fundamentals

Info

LXRX Fundamentals